Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01573052 · ClinicalTrials.gov registry record · Phase 4
Gabapentin vs Chlordiazepoxide for Ambulatory Alcohol Withdrawal
A Phase 4 study, sponsored by VA Salt Lake City Health Care System.
- Completed
- Registry status
- Phase 4
- Development phase
- 26
- Enrollment target
NCT01573052: Completed Phase 4 study, sponsored by VA Salt Lake City Health Care System.
NCT01573052 is a Phase 4 study that has completed, run by VA Salt Lake City Health Care System. The registered enrollment target is 26 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01573052, a Phase 4 study, has completed, sponsored by VA Salt Lake City Health Care System.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 26 participants
- Enrollment target
Study Summary
A randomized, double-blind controlled trial comparing treatment outcomes between chlordiazepoxide, or gabapentin to treat alcohol withdrawal syndrome in alcohol dependent veteran subjects. The objective of this trial is to compare the safety and effectiveness of these two medications. Intervention is a fixed dose taper of chlordiazepoxide, or gabapentin over 6 days. Subjects will be evaluated for 7-10 days to monitor alcohol abstinence, withdrawal severity scores, adverse events including ataxia, sedation, cognitive function and alcohol craving.
Primary Outcome
ESS is an 8 item-scale and scores range between 0 and 24. The higher the score implies more daytime sleepiness.
Interventions
- DRUG Gabapentin
- DRUG Chlordiazepoxide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2004-03 |
| Est. Completion | 2010-09 |
| Phase | Phase 4 |
What the finished NCT01573052 record still lists
NCT01573052 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Gabapentin is the first listed.
NCT01573052 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01573052 about?
NCT01573052 is a clinical study titled "Gabapentin vs Chlordiazepoxide for Ambulatory Alcohol Withdrawal". A randomized, double-blind controlled trial comparing treatment outcomes between chlordiazepoxide, or gabapentin to treat alcohol withdrawal syndrome in alcohol dependent veteran subjects. The objective of this trial is to compare the safety and effectiveness of these two medications. Intervention i...
What is the current status of trial NCT01573052?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 26 participants. The study started on 2004-03. Estimated completion is 2010-09.
What interventions are being tested in trial NCT01573052?
The interventions under investigation include: Gabapentin (DRUG), Chlordiazepoxide (DRUG).
Who is sponsoring clinical trial NCT01573052?
This trial is sponsored by VA Salt Lake City Health Care System, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01573052's enrollment target sits among peer trials
26 1655th of 2000 higher than 332 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia